Galantos Pharma secures €4.4m

Mareen Goebel
05 May 2010

Tweet
Facebook
LinkedIn
Google plus
Send to

A large consortium of state and regional entities has backed drug company Galanthos Pharma with €4.4m of series C of funding.

The investor syndicate for the deal included Rhineland Palatinate Fund VRP, German state bank KfW, Investment Bank Rhineland FIB, Venture Fund Rhineland Palatinate WFT, High-Tech Gründerfonds and the German Ministry for Education and Research

Mainz-based Galantos Pharma GmbH was founded in 2005 and develops medication for neurodegenerative diseases with a focus on Alzheimer's dementia.

It develops neuroprotective and preventive pharmaceuticals parallel to the optimization of the approved natural compound galantamine.

Tweet
Facebook
LinkedIn
Google plus
Send to

Funds

Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

05 September 2023

Buyouts

Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

04 September 2023

Exits

Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

04 September 2023

Investments

Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

04 September 2023